| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 96.35 mm | 96.35 mm | 96.35 mm | 96.35 mm | 96.35 mm | 96.35 mm |
| Cash burn (monthly) | 14.69 mm | 706.25 k | 9.87 mm | 10.36 mm | 8.65 mm | 9.14 mm |
| Cash used (since last report) | 427.07 mm | 20.54 mm | 286.99 mm | 301.16 mm | 251.63 mm | 265.76 mm |
| Cash remaining | -330.72 mm | 75.81 mm | -190.65 mm | -204.81 mm | -155.29 mm | -169.42 mm |
| Runway (months of cash) | -22.5 | 107.3 | -19.3 | -19.8 | -17.9 | -18.5 |
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 4.92 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 4.92 mm | $0.00 |
| Proequities | 0.00 | $0.00 |
